A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma (ROSEWOOD)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03332017 |
Recruitment Status :
Active, not recruiting
First Posted : November 6, 2017
Last Update Posted : February 24, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Relapsed/Refractory Follicular Non-Hodgkin Lymphoma | Drug: Zanubrutinib Drug: Obinutuzumab | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 217 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined With Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/ Refractory Follicular Lymphoma |
Actual Study Start Date : | November 15, 2017 |
Estimated Primary Completion Date : | October 2022 |
Estimated Study Completion Date : | November 2023 |
Arm | Intervention/treatment |
---|---|
Experimental: Arm A
Approximately 140 subjects to receive BGB-3111 and obinutuzumab
|
Drug: Zanubrutinib
BGB-3111 will be administered as two 80-mg capsules by mouth twice a day (160 mg twice a day)
Other Names:
Drug: Obinutuzumab Obinutuzumab will be administered 1,000 mg intravenously on days 1, 8, and 15 of cycle 1, then 1,000 mg on day 1 of cycles 2 to 6, then 1,000 mg every 8 weeks. 1 cycle = 28 days.
Other Name: Gazyva |
Experimental: Arm B
Approximately 70 subjects to receive obinutuzumab
|
Drug: Obinutuzumab
Obinutuzumab will be administered 1,000 mg intravenously on days 1, 8, and 15 of cycle 1, then 1,000 mg on day 1 of cycles 2 to 6, then 1,000 mg every 8 weeks. 1 cycle = 28 days.
Other Name: Gazyva |
- Overall response rate (ORR) as Assessed by Independent Central Review [ Time Frame: up to 3 years ]
- Overall response rate (ORR) as Assessed by the Investigator [ Time Frame: up to 3 years ]
- Duration of response (DOR) [ Time Frame: up to 3 years ]
- Progression free survival (PFS) [ Time Frame: up to 3 years ]
- Overall Survival (OS) [ Time Frame: up to 3 years ]
- Complete Response Rate [ Time Frame: up to 3 years ]
- Complete Metabolic Response Rate [ Time Frame: up to 3 years ]
- Health-Related Quality of Life (HRQOL) as Assessed by The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) [ Time Frame: up to 3 years ]
- Health-Related Quality of Life (HRQOL) as Assessed by The 5-level EQ-5D version (EQ-5D-5L) [ Time Frame: up to 3 years ]
- Time to response (TTR) [ Time Frame: up to 3 years ]
- Occurrence and severity of treatment-emergent adverse events (TEAEs) [ Time Frame: up to 3 years ]Safety and Tolerability

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 99 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Key Inclusion Criteria:
- Histologically confirmed diagnosis of B-cell follicular lymphoma
- ≥2 prior systemic treatments for follicular lymphoma.
- Previously received an anti-CD20 antibody and an appropriate alkylator-based combination therapy.
- Disease progression after completion of most recent therapy or refractory disease.
- Presence of measurable disease.
- Availability of archival tissue confirming diagnosis.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0,1 or 2.
- Adequate renal and hepatic function.
Key Exclusion Criteria:
- Prior exposure to a Bruton's tyrosine kinase (BTK) inhibitor.
- Known central nervous system involvement by leukemia or lymphoma.
- Evidence of transformation from follicular lymphoma to other aggressive histology.
- Allogeneic hematopoietic stem cell transplantation within 12 months of enrollment
- Prior malignancy within the past 2 years, except for curatively treated basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix of breast, or localized Gleason score 6 prostate
- Clinically significant cardiovascular disease.
- Major surgery or significant injury ≤ 4 weeks prior to start of study treatment.
- Active fungal, bacterial or viral infection requiring systemic treatment.
- History of severe bleeding disorder.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03332017

Responsible Party: | BeiGene |
ClinicalTrials.gov Identifier: | NCT03332017 |
Other Study ID Numbers: |
BGB-3111-212 2017-001552-54 ( EudraCT Number ) |
First Posted: | November 6, 2017 Key Record Dates |
Last Update Posted: | February 24, 2022 |
Last Verified: | February 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Relapsed/Refractory Follicular non-Hodgkin Lymphoma |
Lymphoma Lymphoma, Follicular Lymphoma, Non-Hodgkin Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders |
Immune System Diseases Obinutuzumab Zanubrutinib Antineoplastic Agents, Immunological Antineoplastic Agents Protein Kinase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |